Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.
Ashley McMillan
Advertisement
Articles by Ashley McMillan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
The Evolving Relationship Between FDA and Biotech
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5